Innate Pharma SA
IPHA1.870USD
-0.070-3.61%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
156.73MMarket Cap
--P/E TTM
More Details of Innate Pharma SA Company
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
Company Info
Ticker SymbolIPHA
Company nameInnate Pharma SA
IPO dateOct 31, 2006
CEOMr. Jonathan Elliot Dickinson
Number of employees- -
Security typeDepository Receipt
Fiscal year-endOct 31
Address117 avenue de Luminy
CityMARSEILLE
Stock exchangeNASDAQ Global Select Consolidated
CountryFrance
Postal code13009
Phone33430303030
Websitehttps://www.innate-pharma.com/
Ticker SymbolIPHA
IPO dateOct 31, 2006
CEOMr. Jonathan Elliot Dickinson
Company Executives
Name
Name/Position
Position
Shareholding
Change
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Mr. Nicola Beltraminelli
Mr. Nicola Beltraminelli
Vice President, Chief Development Officer, Member of the Leadership Team
Vice President, Chief Development Officer, Member of the Leadership Team
--
--
Mr. Frederic Lombard
Mr. Frederic Lombard
Chief Financial Officer, Member of the Leadership Team
Chief Financial Officer, Member of the Leadership Team
--
--
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mr. Henry Wheeler
Mr. Henry Wheeler
Vice President - Investor Relations and Communications, Member of the Leadership Team
Vice President - Investor Relations and Communications, Member of the Leadership Team
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
--
--
Mr. Olivier Martinez
Mr. Olivier Martinez
Member of the Supervisory Board, Representative of Bpifrance Participations
Member of the Supervisory Board, Representative of Bpifrance Participations
--
--
Ms. Claire De Saint-blanquat
Ms. Claire De Saint-blanquat
Vice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team
Vice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team
--
--
Dr. Sally Bennett
Dr. Sally Bennett
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Mr. Nicola Beltraminelli
Mr. Nicola Beltraminelli
Vice President, Chief Development Officer, Member of the Leadership Team
Vice President, Chief Development Officer, Member of the Leadership Team
--
--
Mr. Frederic Lombard
Mr. Frederic Lombard
Chief Financial Officer, Member of the Leadership Team
Chief Financial Officer, Member of the Leadership Team
--
--
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mr. Henry Wheeler
Mr. Henry Wheeler
Vice President - Investor Relations and Communications, Member of the Leadership Team
Vice President - Investor Relations and Communications, Member of the Leadership Team
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AllianceBernstein L.P.
0.07%
Morgan Stanley & Co. International Plc
0.06%
Citadel Advisors LLC
0.03%
Millennium Management LLC
0.01%
Other
99.84%
Shareholders
Shareholders
Proportion
AllianceBernstein L.P.
0.07%
Morgan Stanley & Co. International Plc
0.06%
Citadel Advisors LLC
0.03%
Millennium Management LLC
0.01%
Other
99.84%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
0.07%
Research Firm
0.06%
Hedge Fund
0.04%
Other
99.83%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
17
157.41K
0.17%
-54.22K
2025Q1
22
261.37K
0.29%
-22.81K
2024Q4
23
278.64K
0.34%
-188.16K
2024Q3
25
406.53K
0.50%
-579.77K
2024Q2
27
405.72K
0.50%
-529.94K
2024Q1
29
344.92K
0.22%
-517.69K
2023Q4
32
202.70K
0.25%
-1.13M
2023Q3
36
377.53K
0.47%
-1.02M
2023Q2
36
293.58K
0.36%
-1.21M
2023Q1
33
404.31K
0.50%
-1.20M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AllianceBernstein L.P.
60.75K
0.07%
+36.48K
+150.33%
Jun 30, 2024
Morgan Stanley & Co. International Plc
43.52K
0.05%
--
--
Mar 31, 2025
Citadel Advisors LLC
24.27K
0.03%
+12.41K
+104.73%
Mar 31, 2025
Millennium Management LLC
15.33K
0.02%
+15.33K
--
Mar 31, 2025
UBS Financial Services, Inc.
9.00K
0.01%
+5.49K
+156.44%
Mar 31, 2025
GAMMA Investing LLC
2.23K
0%
+2.23K
--
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
675.00
0%
--
--
Mar 31, 2025
Barclays Bank PLC
307.00
0%
--
--
Mar 31, 2025
Optiver Holding B.V.
101.00
0%
--
--
Mar 31, 2025
Tower Research Capital LLC
3.00
0%
+3.00
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
